| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2012PLoSO...746117H |
| P356 | DOI | 10.1371/JOURNAL.PONE.0046117 |
| P932 | PMC publication ID | 3462182 |
| P698 | PubMed publication ID | 23049692 |
| P5875 | ResearchGate publication ID | 232226789 |
| P50 | author | Erlend B. Smeland | Q17107612 |
| Kanutte Huse | Q64788710 | ||
| June H. Myklebust | Q76432340 | ||
| Morten P Oksvold | Q125351238 | ||
| Sébastien Wälchli | Q41631179 | ||
| Knut Liestøl | Q45381873 | ||
| P2093 | author name string | Ash A Alizadeh | |
| Lise Forfang | |||
| Maren Bakkebø | |||
| May L Bredahl | |||
| Vera I Hilden | |||
| P2860 | cites work | Smad7 antagonizes transforming growth factor beta signaling in the nucleus by interfering with functional Smad-DNA complex formation | Q24302554 |
| SMAD6 contributes to patient survival in non-small cell lung cancer and its knockdown reestablishes TGF-beta homeostasis in lung cancer cells | Q24319956 | ||
| Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data | Q24537656 | ||
| Targeting of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphomagenesis | Q24624863 | ||
| Coordinated expression of microRNA-155 and predicted target genes in diffuse large B-cell lymphoma | Q24648226 | ||
| BMP-6 inhibits growth of mature human B cells; induction of Smad phosphorylation and upregulation of Id1 | Q24806130 | ||
| The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma | Q27824784 | ||
| Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling | Q27860529 | ||
| Smad7 is induced by CD40 and protects WEHI 231 B-lymphocytes from transforming growth factor-beta -induced growth inhibition and apoptosis | Q28139074 | ||
| The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer | Q28145081 | ||
| Bone morphogenetic protein (BMP)-2 induces apoptosis in human myeloma cells | Q28217103 | ||
| Escaping from the TGFbeta anti-proliferative control | Q28240031 | ||
| Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism | Q29617479 | ||
| BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas | Q29622911 | ||
| Reverse engineering of regulatory networks in human B cells | Q30004211 | ||
| Bone morphogenetic proteins inhibit CD40L/IL-21-induced Ig production in human B cells: differential effects of BMP-6 and BMP-7. | Q50993571 | ||
| Decreased expression of bone morphogenetic protein (BMP) receptor type II correlates with insensitivity to BMP-6 in human renal cell carcinoma cells. | Q53908639 | ||
| Balancing BMP Signaling through Integrated Inputs into the Smad1 Linker | Q60325056 | ||
| Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells | Q73387924 | ||
| Bone morphogenetic protein-2/4 signalling pathway components are expressed in the human thymus and inhibit early T-cell development | Q80139081 | ||
| MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas | Q81418207 | ||
| PU.1 protein expression has a positive linear association with protein expression of germinal centre B cell genes including BCL-6, CD10, CD20 and CD22: identification of PU.1 putative binding sites in the BCL-6 promotor | Q81744830 | ||
| Involvement of twisted gastrulation in T cell-independent plasma cell production | Q84102328 | ||
| Aggressive melanoma cells escape from BMP7-mediated autocrine growth inhibition through coordinated Noggin upregulation. | Q30487367 | ||
| Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis | Q33748979 | ||
| TGF-β-induced growth inhibition in B-cell lymphoma correlates with Smad1/5 signalling and constitutively active p38 MAPK | Q33752152 | ||
| B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression | Q34059352 | ||
| The bone morphogenetic protein pathway is inactivated in the majority of sporadic colorectal cancers | Q34777913 | ||
| IL-7 inhibits fibroblast TGF-beta production and signaling in pulmonary fibrosis | Q34790518 | ||
| Tgf-beta superfamily signaling in embryonic development and homeostasis | Q34963093 | ||
| Transforming growth factor-beta signaling in normal and malignant hematopoiesis | Q35217394 | ||
| Controlling cell fate by bone morphogenetic protein receptors. | Q35600636 | ||
| Resistance to TGF-beta 1 correlates with aberrant expression of TGF-beta receptor II in human B-cell lymphoma cell lines | Q35839895 | ||
| Alterations in components of the TGF-beta superfamily signaling pathways in human cancer | Q36323395 | ||
| Bone morphogenetic proteins regulate the developmental program of human hematopoietic stem cells | Q36368023 | ||
| Role of bone morphogenetic proteins in transitional cell carcinoma cells | Q36405736 | ||
| Conditional deletion of Smad1 and Smad5 in somatic cells of male and female gonads leads to metastatic tumor development in mice | Q36421055 | ||
| A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients | Q37381683 | ||
| The emerging role of TGF-beta superfamily coreceptors in cancer. | Q37553118 | ||
| Recent advances in BMP receptor signaling | Q37629355 | ||
| Bone morphogenetic proteins and cancer: review of the literature | Q37665275 | ||
| Bone Morphogenetic Proteins: A critical review | Q37801468 | ||
| Restoration of bone morphogenetic protein receptor type II expression leads to a decreased rate of tumor growth in bladder transitional cell carcinoma cell line TSU-Pr1. | Q38445560 | ||
| Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC. | Q39469388 | ||
| Promoter hypermethylation of the bone morphogenetic protein-6 gene in malignant lymphoma. | Q40118425 | ||
| BMP-6 inhibits human bone marrow B lymphopoiesis--upregulation of Id1 and Id3. | Q40329682 | ||
| Bone morphogenetic protein 2 stimulation of tumor growth involves the activation of Smad-1/5. | Q40358308 | ||
| Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells | Q40518052 | ||
| Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells | Q40604725 | ||
| Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. | Q41078790 | ||
| Differentiation and apoptosis of human germinal center B-lymphocytes | Q41522446 | ||
| Smad6 suppresses TGF-beta-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer | Q41610166 | ||
| Bone morphogenetic proteins and receptors are over-expressed in bone-marrow cells of multiple myeloma patients and support myeloma cells by inducing ID genes | Q43238530 | ||
| Prognostic significance of the expression of Smad4 and Smad7 in human gastric carcinomas | Q44434503 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | B-cell lymphoma | Q4833719 |
| P304 | page(s) | e46117 | |
| P577 | publication date | 2012-10-01 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Role of Smad proteins in resistance to BMP-induced growth inhibition in B-cell lymphoma | |
| P478 | volume | 7 |
| Q49843417 | Artesunate shows potent anti-tumor activity in B-cell lymphoma |
| Q33657811 | BMP-7 induces apoptosis in human germinal center B cells and is influenced by TGF-β receptor type I ALK5 |
| Q28533353 | BMP7 expression correlates with secondary drug resistance in mantle cell lymphoma |
| Q40993075 | Bone Regeneration Using Bone Morphogenetic Proteins and Various Biomaterial Carriers |
| Q38588911 | Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin. |
| Q48108703 | Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. |
| Q41048773 | DNA methylation profiling reveals common signatures of tumorigenesis and defines epigenetic prognostic subtypes of canine Diffuse Large B-cell Lymphoma. |
| Q42503470 | Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling |
| Q36472101 | Effect of alendronate sodium on the expression of mesenchymal-epithelial transition markers in mice with liver fibrosis |
| Q37429726 | MicroRNA-155 controls RB phosphorylation in normal and malignant B lymphocytes via the noncanonical TGF-β1/SMAD5 signaling module |
| Q38220764 | SMAD7: a timer of tumor progression targeting TGF-β signaling |
Search more.